BioCryst Pharmaceuticals is seeing increased investor activity and conversation centered on its potential for a short squeeze, driven by significant short interest and speculation regarding future M&A activity. The community is closely monitoring upcoming earnings and pipeline data, specifically around the navenibart program, as a potential catalyst to move the stock out of its long-term trading range.
Want to see this trending summary?